مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

الاستراتيجية الوطنية للتحصين للأعوام ٢٠١٧-٢٠٢٢


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    111
    ...
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
N05AX12 JOSWE ARIPAL 10 G Aripiprazole - 10mg 10mg Tablet 2,210,621 L.L
B03BB01 FOLICIL G Folic acid - 5mg 5mg Tablet 584,571 L.L
N05AX12 PIRIFY G Aripiprazole - 10mg 10mg Tablet 795,555 L.L
N07CA01 VERTINEX G Betahistine dihydrochloride - 16mg 16mg Tablet 371,157 L.L
N05AX12 XALIPRO G Aripiprazole - 10mg 10mg Tablet 2,123,271 L.L
N07CA01 VASOSERC G Betahistine dihydrochloride - 8mg 8mg Tablet 1,334,884 L.L
C07AB07 BISCORDEX G Bisoprolol fumarate - 10mg 10mg Tablet 789,667 L.L
M04AC01 COLCHICINE SEID G Colchicine - 1mg 1mg Tablet 382,995 L.L
N07CA01 BETAHISTINE ARROW GENERIQUES G Betahistine dihydrochloride - 24mg 24mg Tablet 749,864 L.L
M05BA04 FOSAMAX 70MG ONCE WEEKLY B Alendronate - 70mg 70mg Tablet 1,988,887 L.L
N05AX12 JOSWE ARIPAL 30 G Aripiprazole - 30mg 30mg Tablet 4,687,323 L.L
N07CA01 VASOSERC BID G Betahistine dihydrochloride - 24mg 24mg Tablet 840,861 L.L
M05BA04 APO-ALENDRONATE G Alendronate (monosodium trihydrate) - 70mg 70mg Tablet 1,173,175 L.L
N05AX12 ABIPREX 15 G Aripiprazole - 15mg 15mg Tablet 1,075,074 L.L
N05AX12 ATYPRAL G Aripiprazole - 15mg 15mg Tablet 712,237 L.L
R05CB06 MUKORAL G Ambroxol - 30mg 30mg Tablet 201,576 L.L
N05AX12 JOSWE ARIPAL 15 G Aripiprazole - 15mg 15mg Tablet 2,413,541 L.L
N05AX12 PIRIFY G Aripiprazole - 15mg 15mg Tablet 795,555 L.L
N07CA03 ZINASEN G Flunarizine (HCl) - 10mg 10mg Tablet 599,354 L.L
M05BA04 STRONDEX 70 G Alendronate sodium - 70mg 70mg Tablet 1,305,447 L.L
N05AX12 XALIPRO G Aripiprazole - 15mg 15mg Tablet 2,418,917 L.L
A11DB 3V G Vitamin B12 - 200mcg, Vitamin B6 - 200mg, Vitamin B1 - 100mg Tablet 229,797 L.L
J01DD13 CEFODOX G Cefpodoxime (proxetil) - 100mg 100mg Tablet 434,061 L.L
C09DA06 ATACAND PLUS B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 705,517 L.L
N05AX12 JOSWE ARIPAL 5 G Aripiprazole - 5mg 5mg Tablet 1,389,533 L.L
R05D 123 COLD AND FLU B Phenylephrine HCl - 5mg, Carbinoxamine HCl - 3mg, Caffeine anhydrous - 30mg, Codeine phosphate - 8mg, Acetaminophen - 325mg Tablet 409,552 L.L
C09DA06 BLOPRESS PLUS 16MG B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 1,257,837 L.L
J01DD13 CEFODOX G Cefpodoxime (proxetil) - 200mg 200mg Tablet 851,996 L.L
N05AX12 PIRIFY G Aripiprazole - 5mg 5mg Tablet 614,328 L.L
C09DA06 ARKANDA PLUS 16/12.5 G Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg 32mg Tablet 854,940 L.L
    ...
    111
    ...
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025